Download PDF

1. Company Snapshot

1.a. Company Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases.The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.


The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease.PTC Therapeutics, Inc.has collaborations with F.


Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc.to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean.PTC Therapeutics, Inc.


was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Show Full description

1.b. Last Insights on PTCT

PTC Therapeutics' recent performance was driven by its robust Q3 results, with total revenue reaching $211 million and a strong launch of Sephience (sepiapterin) for phenylketonuria treatment. The company's quarterly earnings of $0.2 per share beat estimates, marking a significant turnaround. Additionally, the company's presentation at the Citi Annual Global Healthcare Conference and the 44th Annual J.P. Morgan Healthcare Conference showcased its growth prospects. The approval of Sephience in Japan further expanded its market reach.

1.c. Company Highlights

2. PTC Therapeutics' Strong 2025 Performance Sets Stage for Continued Growth

PTC Therapeutics reported a robust financial performance for 2025, with net product and royalty revenue reaching $831 million, exceeding guidance. The company's Q4 2025 revenue was $263 million, with $92 million coming from the newly launched Sephience for PKU. Non-GAAP R&D and SG&A expenses were $728 million, below guidance. The actual EPS came out at '-1.67', relative to estimates at '-0.21', indicating a significant loss. The company's cash position stood at $1.95 billion after selling the remainder of the Evrysdi royalty for $240 million.

Publication Date: Feb -24

📋 Highlights
  • Sephience Launch Success:: Generated $92M in Q4 2025 and $111M since launch, with 80% of US PKU centers of excellence prescribing it and 20–30 international market expansion expected by 2026.
  • Full-Year Revenue Growth:: Net product and royalty revenue reached $831M in 2025 (exceeding guidance), driven by Sephience, with 2026 guidance of $700M–800M (19–36% YoY growth).
  • Strong Cash Position:: Ended 2025 with $1.95B in cash after selling the Evrysdi royalty for $240M, enabling R&D investment and strategic business development.
  • Cost Discipline:: Non-GAAP R&D and SG&A expenses were $728M in 2025 (under guidance), with 2026 guidance of $680M–720M, supporting cash flow breakeven potential.

Revenue Growth and Expense Management

The company's revenue growth was driven by the successful launch of Sephience, with $111 million in revenue since launch. PTC expects Sephience to become a standard of care for PKU, with a potential multibillion-dollar global revenue opportunity. The company's guidance for 2026 product revenue is between $700 million to $800 million, representing 19% to 36% year-over-year growth. Non-GAAP R&D and SG&A expenses are expected to be between $680 million to $720 million.

Valuation Metrics

Analysts estimate next year's revenue growth at 20.8%. The company's current valuation metrics are: P/E Ratio at 8.33, P/B Ratio at -27.71, P/S Ratio at 3.27, EV/EBITDA at 5.81, and Free Cash Flow Yield at 12.35%. These metrics indicate that the market is pricing in a significant growth potential, but also some level of risk given the negative P/B Ratio and relatively low P/E Ratio.

Sephience Launch and Commercial Performance

The launch of Sephience has been successful, with broad uptake across all patient segments and age groups. The company has seen positive feedback from healthcare providers and patients, with 80% of PKU centers of excellence in the US having written prescriptions for one or more patients. As Dr. Matthew Klein mentioned, "adults with PKU still have associations with clinics, and they want to be on therapies," indicating a strong demand for Sephience.

Pipeline Progress and Business Development

PTC is making progress in its pipeline, with the NRF2 activator program showing great activity in kidney and lung studies. The company is also advancing its NLRP3 program, with PTC612 demonstrating strong potency and selectivity. PTC is open to business development opportunities to accelerate top-line growth, with a strong financial position and a focus on maximizing shareholder returns.

3. NewsRoom

Card image cap

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing

Mar -03

Source: fool.com

Card image cap

PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of “Moderate Buy” by Analysts

Feb -27

Source: defenseworld.net

Card image cap

Mark Elliott Boulding Sells 3,019 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

Feb -25

Source: defenseworld.net

Card image cap

PTC Therapeutics to Participate at Upcoming Investor Conferences

Feb -23

Source: prnewswire.com

Card image cap

PTC Therapeutics: Sephience As A Major Growth Driver

Feb -23

Source: seekingalpha.com

Card image cap

PTC Therapeutics (NASDAQ:PTCT) CAO Sells $172,983.84 in Stock

Feb -23

Source: defenseworld.net

Card image cap

Insider Selling: PTC Therapeutics (NASDAQ:PTCT) EVP Sells $172,290.24 in Stock

Feb -23

Source: defenseworld.net

Card image cap

Matthew Klein Sells 7,371 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock

Feb -22

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.00%)

6. Segments

Small Molecule and Gene Therapeutics

Expected Growth: 4.0%

PTC Therapeutics' Small Molecule and Gene Therapeutics segment growth is driven by increasing adoption of Translarna for Duchenne muscular dystrophy, expansion into new markets, and a strong pipeline of novel therapies. Additionally, strategic partnerships and collaborations are expected to fuel growth, along with increasing investment in research and development to address unmet medical needs.

7. Detailed Products

Translarna

A protein synthesis inhibitor for the treatment of nonsense mutations in genetic disorders

Emflaza

A corticosteroid for the treatment of Duchenne muscular dystrophy

Evrysdi

A survival motor neuron 1 (SMN1) splicing modifier for the treatment of spinal muscular atrophy

Waylivra

A treatment for familial chylomicronemia syndrome, a rare genetic disorder

Gene therapy platform

A platform for the development of gene therapies for rare genetic disorders

8. PTC Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

PTC Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for rare genetic disorders. However, the company's focus on developing novel therapies for unmet medical needs reduces the threat of substitutes.

Bargaining Power Of Customers

PTC Therapeutics, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative treatment options for patients with rare genetic disorders.

Bargaining Power Of Suppliers

PTC Therapeutics, Inc. has a moderate bargaining power of suppliers due to its reliance on a few key suppliers for raw materials and manufacturing services. However, the company's strong relationships with suppliers and its diversified supply chain mitigate the risk of supplier concentration.

Threat Of New Entrants

PTC Therapeutics, Inc. has a low threat of new entrants due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development, regulatory approvals, and manufacturing capabilities.

Intensity Of Rivalry

PTC Therapeutics, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry. The company must continually innovate and invest in research and development to stay ahead of its competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight -57.92%
Debt Cost 7.07%
Equity Weight 157.92%
Equity Cost 7.07%
WACC 7.07%
Leverage -36.68%

11. Quality Control: PTC Therapeutics, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
BioMarin Pharmaceutical

A-Score: 4.8/10

Value: 5.0

Growth: 8.4

Quality: 8.0

Yield: 0.0

Momentum: 1.5

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Rhythm Pharma

A-Score: 4.6/10

Value: 6.0

Growth: 5.1

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Celldex Therapeutics

A-Score: 3.8/10

Value: 6.7

Growth: 3.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Denali Therapeutics

A-Score: 3.3/10

Value: 6.7

Growth: 3.7

Quality: 4.5

Yield: 0.0

Momentum: 2.5

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

64.39$

Current Price

64.39$

Potential

-0.00%

Expected Cash-Flows